Skip to content
Recall Observatory FDA recall evidence

Drug product

Limbrel250 (flavocoxid and citrated zinc bisglycinate) 250 mg/50 mg capsules, 60-count bottle, Rx only, Manufactured for: Primus Pharmaceuticals, Inc., Scottsdale, AZ 85253; Manufactured by: Cornerstone Research and Development, Ogden, UT 84404, NDC 68040-605-16.

D-0346-2018

January 26, 2018

Class I

Product summary

Firm
Primus Pharmaceuticals, Inc.
Event
Event 79055
Status
Terminated
Classification
Class I
Quantity
4,006 bottles
Official record key
drug-enforcement:D-0346-2018

Official wording

Reason: Marketed Without An Approved NDA/ANDA: Based on the labeling claims, these products are unapproved drugs for which the safety and efficacy have not been established and, therefore, subject to recall.

Code information: All lots within expiry.

Distribution pattern: Nationwide in the USA.

Derived failure modes

  • Unknown

    reason.no_named_rule · v1.0.0

    Marketed Without An Approved NDA/ANDA: Based on the labeling claims, these products are unapproved drugs for which the safety and efficacy have not been established and, therefore, subject to recall.